R&D News | pharmaphorum

News

AZ, Avillion's Airsupra aces asthma rescue therapy trial

A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy.

News

Mendaera's $73m raise heads digital financings

Recent financings in the digital health sector include a $73 million round for artificial intelligence-enabled robotics player Mendaera, with Qure.ai, VieCure, Rippl, and Univa Health also

News

Genentech buys Regor's next-gen CDK inhibitors for $850M

Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million.

News

Chiesi Biotech Center of Excellence opens to strengthen R&D ...

Chiesi Group has today officially launched its new Biotech Center of Excellence, with the aim that it "brings the future of medicine to Parma."

News

SEC charges Cassava over 'misleading' Alzheimer's claims

The US financial regulator has accepted a $40 million-plus settlement from Cassava Sciences and two of its former executives for making what it alleges are misleading statements about the r

News

Vicebio raises $100m for vaccines and other bio financings

Our periodic round-up of financings in the biotech sector is led by an impressive nine-figure round for UK vaccines developer Vicebio, with GC Therapeutics, Genespire, and 858 Therapeutics

AZ, Avillion's Airsupra aces asthma rescue therapy trial

Mendaera's $73m raise heads digital financings

Genentech buys Regor's next-gen CDK inhibitors for $850M

Chiesi Biotech Center of Excellence opens to strengthen R&D ...

SEC charges Cassava over 'misleading' Alzheimer's claims

Vicebio raises $100m for vaccines and other bio financings

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks